Tissue transglutaminase mediates the pro-malignant effects of oncostatin M receptor over-expression in cervical squamous cell carcinoma

Maria M Caffarel,† Anasuya Chattopadhyay,#† Angela M Araujo, Julien Bauer, Cinzia G Scarpini and Nicholas Coleman*

Department of Pathology, University of Cambridge, UK

*Correspondence to: N Coleman, Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, UK. E-mail: nc109@cam.ac.uk
†These authors contributed equally to this study.
#Current address: Department of Chemistry, University of Cambridge, UK.

Abstract

Oncostatin M receptor (OSMR) is commonly over-expressed in advanced cervical squamous cell carcinoma (SCC), producing a significantly worse clinical outcome. Cervical SCC cells that over-express OSMR show enhanced responsiveness to the major ligand OSM, which induces multiple pro-malignant effects, including increased cell migration and invasiveness. Here, we show that tissue transglutaminase (TGM2) is an important mediator of the ligand-dependent phenotypic effects of OSMR over-expression in SCC cells. TGM2 expression correlated with disease progression and with OSMR levels in clinical samples of cervical and oral SCC. TGM2 depletion in cervical SCC cells abrogated OSM-induced migration on fibronectin-coated surfaces and invasiveness through extracellular matrix, while ectopic expression of TGM2 increased cell motility and invasiveness. Confocal microscopy and co-immunoprecipitation assays showed that TGM2 interacted with integrin–\(\alpha_5\beta_1\) in the presence of fibronectin in cervical SCC cells, with OSM treatment strengthening the interaction. Importantly, integrin–\(\alpha_5\beta_1\) and fibronectin were also over-expressed in cervical and oral SCC, where levels correlated with those of OSMR and TGM2. This combined tissue and in vitro study demonstrates for the first time that stimulation of over-expressed OSMR in cervical SCC cells activates TGM2/integrin–\(\alpha_5\beta_1\)/fibronectin pathway is of biological significance in cervical SCC and a candidate for therapeutic targeting.

Keywords: tissue transglutaminase; oncostatin M receptor; squamous cell carcinoma; cell migration; invasion; integrin–\(\alpha_5\beta_1\); fibronectin

Introduction

Cervical carcinoma is the third most common cause of cancer deaths in women worldwide. Most cases are squamous cell carcinomas (SCCs), which arise from precursor squamous intraepithelial lesions (SILs). Current treatments have not changed for decades and survival rates for advanced disease remain low [1]. It is therefore important to unravel the molecular mechanisms of cervical SCC progression, in order to develop new therapies. A key feature of cervical squamous carcinogenesis is genomic instability, caused by deregulated expression of HPV oncoproteins in proliferating epithelial cells [2,3]. A genomic imbalance that is commonly selected in advanced cervical SCC is copy number gain of chromosome 5p [4,5].

One gene that is likely to drive selection of 5p gain is the oncostatin-M receptor (OSMR; located at 5p13.1), which is commonly up-regulated in cervical SCC and produces a significantly worse clinical outcome when over-expressed, independent of tumour stage [4]. As a cell surface cytokine receptor, OSMR is a novel candidate for therapeutic targeting in cervical SCC. Recently, we showed that over-expressed OSMR enhanced the sensitivity of cervical SCC cells to the major ligand OSM, resulting in the induction of a pro-malignant phenotype. Direct cell effects included increased cell migration and invasiveness, without changes in cell proliferation [6]. Using microarrays, we observed waves of specific gene induction over 72h post-OSM stimulation in OSMR over-expressing cells. The most significant Gene Ontology category groups for the induced genes included angiogenesis, cell invasion/migration and signal transduction. Of particular interest were the 15 genes that also showed an association with OSMR levels in cervical SCC tissue...
samples, as identified from parallel global transcriptional profiling of 29 cases [6]. These genes are listed in our previous publication (see Supplementary material, Table S9, in [6]). They included tissue transglutaminase, also known as transglutaminase 2 (TGM2).

Transglutaminases are calcium-dependent crosslinking enzymes that catalyse post-translational protein modifications. TGM2 is the most diverse and ubiquitously expressed member of the family. Unlike other transglutaminases, TGM2 is a multifunctional protein, which has both enzymatic and non-enzymatic functions. These functions are closely related to its subcellular location and depend on the pathophysiological context [7,8]. TGM2 is over-expressed in a range of cancer types, where it is associated with metastasis and decreased overall patient survival [9–13]. Here we show, for the first time, that OSM–OSMR interactions strongly induce TGM2 expression in SCC cells. The over-expressed TGM2 interacts with integrin–α5β1 in the presence of fibronectin and induces a promalignant phenotype in cervical SCC cells. These in vitro findings are supported by evidence from tissue samples, that high TGM2 expression correlates with neoplastic progression in cervical and oral squamous epithelium, where TGM2 levels correlate with those of OSMR, integrin–α5β1 and fibronectin.

**Materials and methods**

**Human tissue samples**

All tissue samples were used with Local Research Ethics Committee approval. We analysed the following tissue samples and datasets:

- **Set 1**: 29 samples of cervical SCC, 32 samples of lesional epithelium microdissected from cervical high-grade squamous intraepithelial lesions (HSILs) and low-grade SILs (LSILs) and 12 samples of normal ectocervical squamous epithelium, which we previously used for microarray expression analysis [4,6]. Raw data are available at Gene Expression Omnibus (GEO), Accession No. GSE27678. As part of this analysis, we studied the cervical SCCs that showed OSMR copy number gain (n = 13), comparing the cases that showed high-level OSMR overexpression (n = 3) with those that did not (n = 10).

- **Set 2**: 37 samples of cervical SCC, independent of those in set 1, in which OSMR gene copy number had previously been determined by tissue microarray (TMA) fluorescence in situ hybridization (FISH) [4]. TMA sections were used for immunohistochemistry.

- **Sets 3–6**: four additional datasets of cervical and oral SCC samples with published gene expression profiles. The samples represented 32 cervical SCC plus 21 normal cervix (set 3) [5]; 21 cervical SCC, seven HSIL, plus 10 normal cervix (set 4) [14]; 35 oral SCC plus six normal oral mucosa (set 5) [15]; and 22 oral SCC plus five lymph node metastasis (set 6) [16] samples. All microarray data were obtained from the GEO database, with the Accession Nos GSE9750, GSE7803, GSE10121 and GSE2280, respectively.

**Immunohistochemistry**

Sections (5 μm) were cut onto aminopropyltriethoxy silane-coated slides and processed for immunohistochemistry, as described [17]. The primary antibody was mouse monoclonal anti-transglutaminase 2 (Lab Vision, Fremont, CA, USA; TG-100, IgG, 1:100). Briefly, primary antibody (100 μl) was applied in a humidified chamber at 4°C overnight in 1% bovine serum albumin (BSA) in Tris-buffered saline (TBS) containing 0.1% Triton X-100. The slides were then washed in TBS containing 0.025% Triton X-100 and incubated for 1 h with biotinylated goat anti-mouse secondary antibody (1:500; Dako, Glostrup, Denmark). A streptavidin–horseradish peroxidise (HRP) system (Dako) with the substrate diaminobenzidine was used to develop the stain and the slides were counterstained with Harris’s haematoxylin. Negative controls were performed by omitting the primary antibody. We quantified the frequency of TGM2-positive cells, i.e. the percentage of tumour cells that stained positively for TGM2, regardless of intensity.

**Cell culture, OSM treatment and proliferation assays**

We used the representative OSMR over-expressing cervical SCC cell lines, CaSki and SW756, as well as two non-OSMR over-expressing cervical SCC cell lines, MS751 and ME180 [4,6]. The cells were obtained from the American Type Culture Collection (ATCC-LGC, Middlesex, UK) and authenticated by short tandem repeat profiling [18]. Cell culture and OSM treatment were performed as described [6]. OSM was added at 10 ng/ml, in accordance with our previous studies examining long-term effects of OSM in tissue culture [6]. For proliferation assays, cells were trypsinized and counted manually, using a Neubauer chamber. Dead cells were identified with the vital stain Trypan blue (Sigma, St. Louis, MO, USA).

**TGM2 enzymatic activity assay**

The crosslinking activity of TGM2 was measured using the Specific Tissue Transglutaminase Colorimetric Micro assay kit (TG2-CovTest, Covalab, Cambridge, UK), following the manufacturer’s instructions. A standard curve of purified guinea pig TGM2 (specific activity 2200 U/mg) was used to calculate the enzyme activity in each sample.

**siRNA depletion**

As part of multiple complementary approaches to minimize the possibility of non-specific observations, cells were transfected with short interfering RNA
(siRNA), using Lipofectamine RNAiMAX (Invitrogen, Paisley, UK). Four TGM2-specific siRNAs (TGM2 ON-TARGETplus SMARTpool siRNA, Dharmacon, Lafayette, CO, USA) were used in a pool at 40 nM. Non-targeting siRNA and cyclophilin B siRNA (both Dharmacon) were used as negative and positive controls, respectively. The timings of OSM treatment and transfection were optimized to maximize silencing of OSM-induced TGM2. Based on this work (data not shown), OSM was added 6 h after siRNA transfection.

TGM2 over-expression
We used a TGM2–pSG5 expression construct (Agilent Technologies, Santa Clara, CA, USA), kindly provided by Dr In-Gyu Kim, Seoul, Korea. Cells were transiently transfected with 2 µg construct by nucleofection (Amaxa Nucleofector, Lonza, Basel, Switzerland), using 1 × 10^6 cells/transfection for SW756 and 2 × 10^6 cells/transfection for CaSki. Control transfections were performed simultaneously, using 2 µg pmaxGFP expression vector (Amaxa Nucleofector). We compared cells expressing both TGM2 and GFP with those expressing GFP alone.

Cell migration assay
Cells transfected with appropriate siRNAs or over-expression constructs were plated into fibronectin-coated two-chamber migration assay slides (Nunc, Roskilde, Denmark) at 3 × 10^5 cells/chamber. After 24 h, the medium was temporarily removed and a wound created by a gentle scratch with a sterile 200 µl pipette tip. The cells were washed with phosphate-buffered saline (PBS) immediately and the medium replaced. Wound healing was monitored using time-lapse microscopy (Axiovert Tm200, Zeiss, Thornwood, NY, USA), with images captured every 5 min over a period of 24 h. Average migration velocity for individual cells in each experiment was calculated (Velocity 3D Image Analysis, Perkin-Elmer, Waltham, MA, USA) from 30 randomly chosen cells. This number of cells gave a statistical power > 0.95 for detecting a significant difference (p < 0.05) between experimental and control samples (see Supplementary material, Table S1; http://biostat.mc.vanderbilt.edu/PowerSampleSize). All experiments were performed in triplicate and the mean values used to indicate migration velocities.

Cell invasion assay
Invasion assays were performed using the Cultrex Basement Membrane Extract (BME) Cell Invasion Assay (R&D Systems, Minneapolis, MN, USA), following the manufacturer’s instructions; 0.5 × 10^6 OSM-stimulated/unstimulated control-treated or siRNA-treated cells were seeded in the top chamber at the start of each assay. Standard curves for each SCC cell line were used to convert fluorescence values into cell number. All experiments were performed in triplicate and the mean values used to indicate invasion.

Western blotting
Whole-cell lysates were subjected to SDS–PAGE and proteins transferred onto polyvinylidene fluoride membranes. The following primary antibodies were used: TGM2 (Lab Vision; 1:1600 and CST, Danvers, MA, USA; 1:1000); Fak (1:1000; CST); OSMRβ (1:500; Santa Cruz Biotechnology, Dallas, TX, USA); integrin–α5 (1:2000), integrin–β1 (1:1000) and P-Fak (Y397, 1:1000) (all BD Biosciences, San Jose, CA, USA); and β-actin (1:100000; Abcam, Cambridge, UK). Secondary HRP-conjugated antibodies (1:1000) were from Dako. Luminograms were obtained with the Amersham Enhanced Chemiluminescence Detection Kit (GE Healthcare, Uppsala, Sweden) and densitymetry performed using FluorChem-9900 imaging system software (Alpha-Innotech, San Leandro, CA, USA).

Real-time quantitative PCR
Relative mRNA transcript levels were measured in triplicate using QuantiTect One-Step SYBR-Green qRT–PCR (Qiagen, Crawley, UK), following reverse transcription of 1 µg total RNA using QuantiTect Reverse Transcription (Qiagen). Primers were obtained from Qiagen (Quantitect primers) or PrimerBank (see Supplementary material, Table S2). Expression ratios were calculated using the comparative threshold cycle (Ct) method [19] and normalized using three housekeeping genes; ACTB, TBP and HMBS [20].

Flow cytometry
Live non-permeabilized cells detached with trypsin were stained at 4°C with anti-TGM2 (1:100; Lab Vision) or anti-integrin–α5β1 (1:100, clone HA5; Milipore, Temecula, CA, USA) antibodies. After incubation with secondary Alexa 488 conjugated antibody (1:100; Molecular Probes, Leiden, The Netherlands), cells were analysed using a CyAn ADP flow cytometer (DakoCytomation, Glostrup, Denmark). Isotypic control IgG and an appropriate fluorochrome-conjugated secondary antibody were used in parallel as a negative control. The data were analysed using Summit 4.3 software (DakoCytomation).

Immunofluorescence staining
Cells were seeded on fibronectin-coated coverslips, treated with OSM for 48 h and fixed using 4% paraformaldehyde for 10 min at room temperature. They were stained by immunofluorescence (IF) as described [17], using an anti-TGM2 rabbit monoclonal antibody (1:100; CST) and an anti-integrin–α5 mouse monoclonal antibody (1:100; Abcam). Alexa 488 conjugated goat anti-rabbit and Alexa 594 conjugated goat anti-mouse (1:1000; Molecular Probes) were used as secondary antibodies, with Hoechst 33258 (Sigma).
nuclear counterstaining. Cells were examined by confocal laser-scanning microscopy (Zeiss LSM 510).

Immunoprecipitation

Cells were washed with PBS and lysed in ice-cold RIPA buffer containing 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 50 mM Tris–Cl, pH 7.5, and protease and phosphatase inhibitor cocktail tablets (Roche, Penzberg, Germany). The lysates were incubated for 15 min at 4 °C on a rotating wheel and precleared by centrifugation at 13 000 rpm for 10 min. Non-specific binding was reduced by pre-incubating the lysates with protein G-Sepharose (GE Healthcare) for 20 min at 4 °C. Total cellular protein, 1 or 2 mg (from SW756 or CaSki, respectively) were immunoprecipitated overnight at 4 °C with 10 µl anti-integrin–α5β1 antibody (clone JBS5, Millipore) or normal mouse IgG (Millipore, used as negative control), followed by incubation with protein G-Sepharose for a further 4 h. The complexes were harvested by centrifugation, washed five times with PBS 0.1% Triton X-100, resolved in SDS–PAGE and immunoblotted.

Pathway enrichment analysis

We performed comparative pathway analysis of two mRNA expression datasets obtained in our previous microarray profiling study [6]. The first set was derived from cervical SCCs in sample set 1, that showed OSMR copy number gain and represented genes differentially expressed (p < 0.05) in the cases that showed high-level OSMR over-expression (n = 3), compared with those that did not (n = 10). This dataset was determined using Affymetrix U133 Plus 2.0 arrays (Santa Clara, CA, USA). The second set represented genes differentially expressed (p < 0.05) in CaSki or SW756 cells after OSM treatment, comparing cells at 12, 24 and 48 h time points with untreated (time 0 h) cells. This dataset was determined using Human Whole Genome 6 Expression Bead Chips v 2 (Illumina, San Diego, CA, USA). Pathway analysis was done using DAVID software [21,22], using platform-specific probe IDs. Background was set as Homo sapiens to avoid any platform bias. The categories searched were GO_BP, KEGG_PATHWAY, BIOCARTA and BBID. Functional annotation clusters and charts were saved and processed with PYTHON scripts, in order to match common information between the tissue sample and cell line annotation clusters. Pathways were considered to be shared between the clusters if the Benjamini adjusted p value was < 0.1 for both the tumour samples, and for either CaSki or SW756 at one or more of the time points analysed.

Statistics

We used ANOVA, with a post hoc analysis by the Student–Newman–Keuls’ test. Unless otherwise stated, results are expressed as mean ± standard error of the mean (SE).

Results

TGM2 is over-expressed and correlates with OSMR levels in human SCCs

In our previous study of sample set 1, TGM2 was significantly up-regulated in cervical SCC samples with OSMR over-expression, compared with those that lacked OSMR over-expression [6]. There was no association between OSMR and TGM2 gene copy number in this sample set, as assessed by comparative genomic hybridization (data not shown). Using linear regression analysis, we found that levels of TGM2 mRNA correlated significantly with those of OSMR in all the set 1 SCC samples (n = 29; Figure 1A). The frequency of TGM2-positive cells, as determined by immunohistochemistry, was also significantly higher in sections of the 19 cervical SCC samples from set 2 that showed OSMR copy number gain, versus the 18 samples that lacked OSMR copy number gain (Figure 1B).

In view of these findings, we interrogated published data from gene expression profiling of cervical and oral SCC (sets 3–6), as well as our cervical SILs dataset (set 1). This showed that TGM2 expression correlated with disease progression in cervical tissue samples (Figure 1C, D). In set 1, TGM2 expression was higher in SILs than in normal cervix and was significantly increased in HSILs versus LSILs (Figure 1C). In set 3, TGM2 levels were increased in SCC samples compared to normal cervix (Figure 1D), and there was a positive correlation between levels of TGM2 and OSMR (see Supplementary material, Figure S1A). The correlation of TGM2 expression with disease progression was further validated in cervical sample set 4, in which expression levels increased progressively between normal cervix, HSILs and SCCs (see Supplementary material, Figure S1B).

Oral SCC samples (set 5) also showed overexpression of TGM2 compared to normal oral mucosa, with a positive correlation between levels of TGM2 and OSMR (Figure 1E). In an independent dataset of oral samples (set 6), TGM2 expression was higher in lymph node metastases than in the corresponding primary tumours and in a separate set of non-metastatic oral SCCs (see Supplementary material, Figure S1C). Again, there was a correlation between levels of TGM2 and OSMR in the oral SCCs and metastases from set 6 (see Supplementary material, Figure S1D).

OSM-induced TGM2 enhances migration and invasion of cervical SCC cells

As the evidence from human tissue samples suggested an important role for TGM2 in SCC progression, we examined the functional significance of TGM2 in cervical SCC cells in vitro. We used multiple complementary experimental approaches, based on gene
Figure 1. TGM2 expression in cervical and oral SCCs. (A) Linear regression analysis of mRNA levels of TGM2 versus OSMR in microarray expression data for cervical SCC samples (set 1). (B) Correlation between TGM2 protein expression and OSMR copy number in cervical SCC samples (set 2). The left-hand panels show representative images from immunohistochemical staining for TGM2 in cervical SCC samples in which OSMR copy number gain was present (OSMR-G; top row) or absent (OSMR-N; bottom row); scale bars = 100 µm. The right-hand box plot shows the frequency of TGM2-positive SCC cells in samples where OSMR copy number gain was present (OSMR-G) or absent (OSMR-N): bar, median; box, IQR; whiskers, range. (C, D) Expression of TGM2 mRNA in cervical neoplastic progression. TGM2 mRNA expression in normal cervix samples, LSILs, HSILs and SCCs was determined from microarray data derived from sample sets 1 (C) and 3 (D). (E) Expression of TGM2 in oral SCC, based on expression microarray data for sample set 5. The left panel shows levels of TGM2 mRNA in normal oral mucosa and oral SCC tissues, while the right panel shows linear regression analysis of TGM2 mRNA levels versus OSMR mRNA levels in the oral SCC samples.
Figure 2. Effect of TGM2 depletion and over-expression on the migration and invasiveness of OSMR over-expressing cervical SCC cells. (A) Western blot showing levels of TGM2 protein in SW756 and CaSki at 24–72 h in control cells treated with vehicle only (C) or in OSM–treated cells (OSM). β-Actin (lower row) was used as the loading control. The graphs below each blot represent the densitometric analysis of protein levels. Results are expressed as optical density (arbitrary units), with control cells set as 1. (B) Levels of TGM2 enzymatic activity in SW756 and CaSki cells after 48 h in the absence (−OSM) or presence (+OSM) of OSM. (C, D) Quantification of cell migration velocity (C) and invasiveness through basement membrane extract (D). Each panel shows data for SW756 (left column) and CaSki (right column) following TGM2 depletion (top row) or TGM2 over-expression (bottom row). In the depletion experiments, cells were assayed after 48 h in the presence (+OSM) or absence (−OSM) of OSM. Cells with TGM2 knock-down (KD) were compared with control cells treated with non-targeting (NT) siRNA. As background levels of TGM2 were barely detectable in CaSki (see A), TGM2 depletion was only performed in OSM–treated CaSki cells. In the over-expression experiments, cells expressing TGM2 and GFP (GFP + TGM2) were compared with control cells expressing GFP alone: ns, non-significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001

© 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
on fibronectin-coated surfaces, as well as invasion through extracellular matrix (Figure 2C, D, upper panels; see also Supplementary material, Figure S5). Conversely, ectopic TGM2 over-expression (see Supplementary material, Figure S4B–D) significantly increased the motility and invasiveness of both cell lines in the absence of OSM stimulation (Figure 2C, D, lower panels). TGM2 depletion and over-expression had no effect on cell proliferation and viability in the time frame of the invasion experiments (see Supplementary material, Figure S6). Together, these results demonstrated that TGM2 was a significant mediator of the pro-migratory and pro-invasive effects of OSM in OSMR over-expressing cervical SCC cells.

TGM2 interacts with integrin–α5β1 in cervical SCC cells in an OSM-dependent manner

Another of the 15 genes that were induced by OSM in OSMR-over-expressing cervical SCC cells, and also associated with OSMR over-expression in cervical SCC tissues [6], was integrin–α5 (ITGA5). As TGM2 has been reported to interact with integrin–α5β1 in mesenchymal cells, leading to binding of the cognate ligand fibronectin [23,24], we examined interactions between OSMR, TGM2, integrin–α5β1 and fibronectin in cervical SCC cells. OSM increased integrin–α5 (ITGA5), integrin–β1 (ITGB1) and fibronectin (FN1) mRNA levels in both SW756 and CaSki (see Supplementary material, Figure S2). After 48 h of OSM treatment, integrin–α5 protein levels increased 7.1- and 2.9-fold for SW756 and CaSki, respectively (Figure 3A). Integrin–β1 protein expression was also induced by OSM in CaSki, with a 1.5-fold increase at 48 h. Basal levels of integrin–β1 protein in SW756 were very high and expression did not increase further upon OSM treatment (Figure 3A). In the OSMR non-over-expressing cervical SCC cells MS751 and ME180, OSM did not induce integrin–α5 or integrin–β1 (see Supplementary material, Figure S3).

By flow cytometry, we observed that OSM treatment significantly increased expression of integrin–α5β1 dimers at the cell surface in both SW756 and CaSki (Figure 3B). The function of TGM2 relates to its subcellular location, with cell surface protein being responsible for interactions with integrins [8]. Flow cytometry demonstrated the presence of TGM2 on the cell surface of both SW756 and CaSki (Figure 4A). OSM treatment increased the levels of membrane-associated TGM2, although the differences did not reach statistical significance. Confocal microscopy confirmed the cell membrane localization of TGM2 and showed focal co-localization of TGM2 and integrin–α5 in control and OSM-treated SW756 cells grown on fibronectin (Figure 4B).

Immunoprecipitation with an antibody against integrin–α5β1 confirmed that TGM2 interacted physically with integrin–α5β1 in SW756 and showed that OSM treatment strengthened the interaction (Figure 4C left, lanes 3 and 4). In CaSki, the interaction between TGM2 and integrin–α5β1 was only seen in OSM-stimulated cells (Figure 4C right, lanes 3 and 4), in agreement with the very low levels of TGM2 in unstimulated (control) cells (Figure 2A). For both cell lines, most of the TGM2 remained in the fraction unbound by the anti-integrin–α5β1 antibody (Figure 4C, lanes 5 and 6 in both panels). This was supported by our observation that most TGM2 is cytoplasmic in cervical SCC cells (Figure 4B) and was consistent with findings from mesenchymal cells [23]. In the immunoprecipitation experiments, normal mouse IgG, used as an isotype control, failed to pull down TGM2 and integrin–α5β1 (Figure 4C, lanes 7 and 8 in both panels), confirming the specificity of the interaction between TGM2 and integrin–α5β1.

We next investigated whether OSM contributed to integrin-dependent signal transduction. In SW756 cells cultured on fibronectin, OSM treatment increased the levels of activated (Y397-phosphorylated) focal adhesion kinase (Fak), a known early marker of integrin activation that mediates cell adhesion, migration and invasion [25] (Figure 4D). Levels of activated Fak versus total Fak increased 2.7-fold in OSM-treated cells, compared with control-treated cells. CaSki cells showed high basal levels of phosphorylated Fak (similar to SiHa cervical SCC cells grown on fibronectin [26]), which were not increased further by OSM treatment (Figure 4D).

Integrin–α5β1 and fibronectin are over-expressed and correlate with OSMR and TGM2 levels in human SCCs

By interrogating published datasets (sets 3 and 5), we found that integrin–α5β1 and fibronectin were significantly over-expressed in cervical and oral SCCs and that levels of integrin–β1 and fibronectin correlated with those of OSMR and TGM2 (Figure 5). These correlations were validated in our independent dataset of cervical SCCs (set 1), where integrin–α5 levels were also associated with OSMR expression (see Supplementary material, Figure S7, Table S3). In an independent dataset of oral SCCs (set 6), levels of integrin–α5β1 and fibronectin again correlated with those of OSMR, while integrin–α5 and fibronectin levels correlated with TGM2 expression (see Supplementary material, Figure S7).

Finally, we analysed pathways that were enriched in the OSMR-over-expressing versus non-over-expressing cervical SCCs from sample set 1, adopting the very stringent approach used in our previous study [6] (see Materials and methods). In total, 90 pathways were significantly enriched. Eight of the 21 top-ranking pathways (ranked by adjusted p value) were related to cell migration, adhesion and extracellular matrix (ECM) interactions (Table 1). Four of these pathways were also enriched in OSM-treated CaSki or SW756.
Figure 3. Integrin–α5β1 expression in cervical SCC cells. (A) Western blot analysis of total levels of integrin–α5 (ITGA5) and integrin–β1 (ITGB1) in SW756 and CaSki, comparing OSM-treated cells (OSM) with control cells treated with vehicle only (C); β-actin (lower row) was used as the loading control. (B) Flow-cytometric measurement of cell surface integrin–α5β1 in SW756 and CaSki cells, comparing cells treated with OSM for 48 h (OSM) with control cells treated with vehicle only (C). Negative control cells were stained with an isotype control IgG. In the graphs (bottom row) statistical comparisons were between OSM-treated and control-treated cells: **p < 0.01; ***p < 0.001.

cells, compared with untreated cells. Together, these findings further supported our evidence of associations between OSMR, TGM2, integrin–α5β1 and fibronectin that promoted pro-malignant phenotypic changes in cervical SCC cells.

Discussion

These combined tissue sample and in vitro data represent the first demonstration that TGM2 is an important mediator of the ligand-dependent pro-malignant effects of OSMR over-expression in cervical SCC cells. OSM is a member of the IL-6 cytokine family, and is known to signal through JAK–STAT pathways to activate context-dependent target genes [27]. We previously demonstrated that OSM induced STAT3 activation in an OSMR-dependent manner in cervical SCC cells [4], and others have shown that STAT1 and STAT5 can also be activated by OSM–OSMR binding [27]. Interestingly, there are putative STAT binding sites in the TGM2 promoter [28]. Our data suggest that OSM–OSMR interactions may also be responsible for inducing TGM2 in other cell types, such as breast cancer cells, in which OSM promotes cell motility and metastatic behaviour and TGM2 has been associated with migration, invasion and metastasis [29–33]. In support of this, TGM2 was identified by microarray analysis as one of the genes up-regulated in T47D breast cancer cells after OSM treatment [34].

Our analyses of multiple independent clinical sample sets demonstrate that expression of TGM2 increases during squamous neoplastic progression in the cervix and oral cavity. In the cervix, levels increased between normal cervix, SIL and SCC, while elevated levels were also seen in oral SCC, with higher expression in metastases compared to non-metastatic tumours. These findings are supported by previous immunohistochemical studies of clinical samples. TGM2 expression was higher in cervical SILs and SCCs than in normal cervical squamous epithelium [35], while high TGM2 expression in laryngeal SCC was associated with decreased overall survival in patients treated by surgery and radiotherapy [36].

Together, our results suggest the existence of a biologically significant OSMR/TGM2/integrin–α5β1 pathway in cervical and oral SCC. TGM2–integrin–fibronectin associations have previously been implicated in the cell motility and invasion of breast cancer cells, compared with untreated cells.
Figure 4. Interactions between TGM2 and integrin–α5β1 in cervical SCC cells. (A) Flow-cytometric quantification of cell-surface TGM2 expressed by SW756 and CaSki, comparing cells treated with OSM for 48 h (OSM) with control cells treated with vehicle only (C). Negative control cells were stained with an isotype control IgG. (B) Immunofluorescence for TGM2 (green) and integrin–α5 (red) in SW756 cells treated with vehicle (control) or OSM (48 h) for 48 h, showing focal co-localization (yellow); scale bars = 10 μm. (C) Immunoprecipitation showing physical interaction between TGM2 and integrin–α5β1 in SW756 and CaSki. Cells cultured on fibronectin-coated plates and treated with vehicle (C) or OSM (OSM) for 48 h were immunoprecipitated with anti-integrin–α5β1 antibodies or with IgG isotype-matched control antibodies. The immunoprecipitated (IP) and unbound (UNB) fractions, together with whole-cell lysates, were then analysed by western blotting, using antibodies against TGM2 (top row), integrin–α5 (ITGA5; middle row) and integrin–β1 (ITGB1; bottom row). The anti-integrin–α5β1 antibody precipitated TGM2 in both cell lines (cf lanes 3 and 4 versus 7 and 8 for each panel), with a stronger band for SW756 than for CaSki. Increased levels of precipitated protein were seen in OSM-treated cells (cf lanes 4 versus 3 in each panel). (D) Western blot showing levels of Y397-phosphorylated Fak (P-Fak) and total Fak in SW756 and CaSki cells cultured on fibronectin-coated plates and treated with OSM or vehicle (C) for 48 h.
Figure 5. Integrin-α5β1 and fibronectin expression in cervical and oral SCCs. The panels show data derived from microarray analysis of (A) cervical SCCs (sample set 3) and (B) oral SCCs (sample set 5). In each panel, the top row shows levels of integrin-α5 (ITGA5; left), integrin-β1 (ITGB1; middle) and fibronectin (FN1; right) in normal mucosa and SCC tissues, while the middle and bottom rows show linear regression analysis of expression of ITGB1 and FN1 versus OSMR (middle) or TGM2 (bottom) in the SCC samples.

While integrin-α5β1 is usually expressed at low or undetectable levels in most adult epithelia, it is highly up-regulated in some tumours, including melanomas and lung carcinomas, where high expression levels correlate with advanced disease and reduced patient survival [37]. Integrins control ECM remodelling, which is necessary for cancer cell migration and invasion. Indeed, over-expression of fibronectin and other ECM proteins has been associated with cancer progression and metastasis [38]. Individually, integrin-α5, fibronectin and other ECM proteins have been shown to be over-expressed in cervical SCC samples compared with normal cervical epithelium [39–41]. Fibronectin and other
ECM proteins were also up-regulated in oral SCC, where they were associated with lymph node metastasis [42]. These data reinforce our evidence that the TGM2–integrin–α5β1–fibronectin interactions that are activated by OSMR stimulation in SCC cells are of biological and clinical significance.

Our findings further strengthen the interest in antibody-based inhibition of OSM–OSMR binding as a novel cancer therapeutic strategy. Humanized antibodies against OSM are showing considerable promise in treating rheumatoid arthritis, where they are able to inhibit lymphocyte migration and reduce inflammation [43]. Our accumulated data ([4,6] and the present study) suggest that analogous benefits will also be obtained in cervical SCC (and potentially other tumour types where OSMR is over-expressed), by reducing tumour cell migration and invasion. It may be possible to increase therapeutic efficacy through simultaneous targeting of other points in the OSMR/TGM2/integrin–α5β1/fibronectin pathway. For example, TGM2 inhibitors have been shown to be effective in preclinical models of glioblastoma, where they cooperated with chemotherapy in reducing tumour growth by disrupting fibronectin assembly [44], while small molecules and antibodies targeting integrin–α5β1 are currently being used in clinical trials to block tumour angiogenesis [37]. In vivo studies using appropriate preclinical models are now required to test the clinical benefits of targeting this functionally significant pathway in cervical SCC cells.

Acknowledgements

We thank Sara Pensa and Isabel Peset for advice on immunoprecipitation; and Dawn Ward, Pamela Stacey and Emma Knight for assistance with immunohistochemistry. Financial support was from Cancer Research UK and the Medical Research Council.

Author contributions

MMC, AC and NC designed the study; MMC, AC, AMA, JB and CGS performed the experiments and acquired the data; and all authors analysed and interpreted the data. MMC and NC wrote the manuscript, with contributions from AC and JB. All authors had final approval of the submitted and published versions.

References

1. Stanley MA. Genital human papillomavirus infections: current and prospective therapies. J Gen Virol 2012; 93: 681–691.
2. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 2007; 212: 356–367.
3. zur Hausen H. Disrupted dichotomous intracellular control of human papillomavirus infection in cancer of the cervix. Lancet 1994; 343: 955–957.
4. Ng G, Winder D, Muralidhar B, et al. Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome. J Pathol 2007; 212: 325–334.
5. Scotto L, Narayan G, Nandula SV, et al. Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol Cancer 2008; 7: 58.
6. Winder DM, Chattopadhyay A, Muralidhar B, et al. Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness. J Pathol 2011; 225: 448–462.
7. Belkin AM. Extracellular TGF: emerging functions and regulation. FERS J 2011; 278: 4704–4716.
8. Wang Z, Griffin M. T2G, a novel extracellular protein with multiple functions. Amino Acids 2012; 42: 939–949.
9. Mehta K, Kumar A, Kim HJ. Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol 2010; 80: 1921–1929.
10. Kumar S, Mehta K. Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship? Amino Acids 2013; 44: 81–88.
11. Jung HJ, Chen Z, Wang M, et al. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. Blood 2012; 119: 2568–2578.
12. Sun Y, Mi W, Cai J, et al. Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res 2008; 7: 3847–3859.
13. Miyoshi N, Ishii H, Minomi K, et al. TGM2 is a novel marker for prognosis and therapeutic target in colorectal cancer. Ann Surg Oncol 2010; 17: 967–972.
14. Zhai Y, Kuick R, Nan B, et al. Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies
HOXC10 as a key mediator of invasion. *Cancer Res* 2007; 67: 10163–10172.

15. Sticht C, Freier K, Knopfle K, et al. Activation of MAP kinase signaling through ERK5 but not ERK1 expression is associated with lymph node metastases in oral squamous cell carcinoma (OSCC). *Neoplasia* 2008; 10: 462–470.

16. O’Donnell RK, Kupferman M, Wei SJ, et al. Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. *Oncogene* 2005; 24: 1244–1251.

17. Freeman A, Morris LS, Mills AD, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. *Clin Cancer Res* 1999; 5: 2121–2132.

18. Muralidhar B, Winder D, Murray M, et al. Functional evidence that Drosha over-expression in cervical squamous cell carcinoma affects cell phenotype and microRNA profiles. *J Pathol* 2011; 224: 496–507.

19. Pfaffl MW. A new mathematical model for relative quantification in real-time RT–PCR. *Nucleic Acids Res* 2001; 29: e45.

20. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT–PCR data by geometric averaging of multiple internal control genes. *Genome Biol* 2002; 3: RESEARCH0034.

21. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat Protoc*. 2009; 4: 44–57.

22. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 2009; 37: 1–13.

23. Akimov SS, Krylov D, Fleischman LF, et al. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. *J Cell Biol* 2000; 148: 825–838.

24. Akimov SS, Belkin AM. Cell-surface transglutaminase promotes fibronectin assembly via interaction with the gelatin-binding domain of fibronectin: a role in TGFβ-dependent matrix deposition. *J Cell Sci* 2001; 114: 2989–3000.

25. McLean GW, Carragho NR, Avizienyte E, et al. The role of focal adhesion kinase in cancer—a new therapeutic opportunity. *Nat Rev Cancer* 2005; 5: 505–515.

26. Maity G, Fahreen S, Banerji A, et al. Oncostatin M-induced fibronectin in human cervical cancer cells (SiHa). *Mol Cell Biochem* 2010; 336: 65–74.

27. Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem J* 2003; 374: 1–20.

28. Krona A, Aman P, Orndal C, et al. Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. *Oncogene* 2007; 26: 2459–2470.

29. Queen MM, Ryan RE, Holzer RG, et al. Breast cancer cells stimulate neutrophils to produce oncostatin M, potential implications for tumor progression. *Cancer Res* 2005; 65: 8896–8904.

30. Jorcyk CL, Holzer RG, Ryan RE. Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast cancer cells. *Cytokine* 2006; 33: 323–336.

31. West NR, Murphy LC, Watson PH. Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer. *Endocr Relat Cancer* 2012; 19: 181–195.

32. Kumar A, Xu J, Brady S, et al. Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. *PLoS One* 2010; 5: e13390.

33. Underhill-Day N, Heath JK, Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor β-specific keratin. *Cancer Res* 2006; 66: 10981–10901.

34. Gupta R, Srinivasan R, Nijhawan R, et al. Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor-κB expression. *Virchows Arch* 2010; 456: 45–51.

35. Jin T, Lin HX, Lin H, et al. Expression TGM2 and BNIP3 have prognostic significance in laryngeal cancer patients receiving surgery and postoperative radiotherapy: a retrospective study. *J Transl Med* 2012; 10: 64.

36. Desgrosellier JS, Cheres D. Integrins in cancer: biological implications and therapeutic opportunities. *Nat Rev Cancer* 2010; 10: 9–22.

37. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. *Nat Rev Cancer* 2009; 9: 285–293.

38. Hazlebag S, Gorter A, Kenter GG, et al. Transforming growth factor-β1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. *Hum Pathol* 2002; 33: 1193–1199.

39. Chen Y, Miller C, Mosher R, et al. Identification of cervical cancer markers by cDNA and tissue microarrays. *Cancer Res* 2003; 63: 1927–1935.

40. Contag SA, Gostout BS, Clayton AC, et al. Comparison of gene expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix. *Gynecol Oncol* 2004; 95: 610–617.

41. Nagata M, Fujita H, Ida H, et al. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. *Int J Cancer* 2003; 106: 683–689.

42. Choi SI, Brah N. Rheumatoid arthritis therapy: advances from bench to bedside. *Autoimmunity* 2010; 43: 478–492.

43. Yuan L, Siegel M, Choi K, et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. *Oncogene* 2007; 26: 2563–2573.

**SUPPLEMENTARY MATERIAL ON THE INTERNET**

**Figure S1.** Validation of TGM2 correlations with OSMR expression and squamous neoplastic progression in the cervix and oral mucosa

**Figure S2.** Expression of TGM2, integrin–α5β1 and fibronectin in OSMR over-expressing cervical SCC cells 24–72 h after OSM treatment

**Figure S3.** Expression of TGM2, integrin–α5β1 and OSMR in non-OSMR-over-expressing cervical SCC cells 24–72 h after OSM treatment

**Figure S4.** Levels and activity of TGM2 in SW756 and CaSki after TGM2 depletion and over-expression

**Figure S5.** Wound healing in SW756 and CaSki cells

**Figure S6.** Effect of TGM2 depletion and over-expression on the proliferation and cell viability of OSMR-over-expressing cervical SCC cells

**Figure S7.** Validation of correlations between levels of integrin–α5β1 and fibronectin versus OSMR and TGM2

**Table S1.** Power calculations for cell migration experiments

**Table S2.** Primers used for real-time quantitative PCR

**Table S3.** Differential expression of selected genes in cervical SCCs according to OSMR levels